

CSD/BSE&NSE/2024-25 November 29, 2024

To The Manager

**Department of Corporate Services** 

**BSE Limited** 

25th Floor, P. J. Towers,

Dalal Street, Mumbai - 400 001

Scrip Code: 543064

Dear Sir/Madam,

**Sub: Credit Rating** 

To

The Manager

**Listing Department** 

National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex

Bandra (E), Mumbai – 400 051

Scrip Symbol: SUVENPHAR

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to intimate you that the CRISIL has assigned the following ratings to the Bank facilities of our Company as per communication received on November 29, 2024.

Facilities	Rating
Long Term Rating	CRISIL A+/Watch Positive (Continues on 'Rating Watch with
	Positive Implications')
Short Term Rating	CRISIL A1+ (Reaffirmed)

This is for your information and record.

Thanking you.

Yours faithfully,

For Suven Pharmaceuticals Limited Digitally signed by

KUNDAN

KUNDAN KUMAR JHA KUMAR JHA Date: 2024.11.29

17:19:58 +05'30'

**Kundan Kumar Jha** 

Company Secretary, Compliance Officer and Head-Legal

## **Suven Pharmaceuticals Limited**

Registered Office: # 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad - 500081 Telangana, India Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com I Website: www.suvenpharm.com I CIN: L24299MH2018PLC422236